Lung Cancer Screening and Prevention Act of 2025
Summary
What This Bill Does
The Lung Cancer Screening and Prevention Act of 2025 amends Social Security Act section 1834(n). Medicare already covers certain lung cancer screening under national coverage determination 210.14; this bill lets the HHS Secretary cover other lung cancer screening tests that are cleared or approved by the Food and Drug Administration as preventive services for appropriate individuals. The Secretary can set frequency and payment limits after consultation with appropriate organizations. The bill creates a faster coverage path for new screening technology without requiring Congress to name each test.
Who Benefits and How
Medicare beneficiaries at lung cancer risk benefit if additional FDA-cleared screening tests become covered preventive services. Lung cancer patients benefit from earlier detection when screening tools reach appropriate high-risk individuals. Medical device manufacturers benefit because FDA-cleared or FDA-approved screening tests can become Medicare-covered services. Radiology providers benefit if Medicare coverage expands demand for preventive lung cancer screening.
Who Bears the Burden and How
The Centers for Medicare and Medicaid Services must decide which tests, patient groups, frequencies, and payment limits are appropriate. Medicare contractors must update claims processing for any newly covered screening tests. Medicare trust funds bear added screening costs when the Secretary expands coverage. Clinical guideline organizations may face consultation demands as HHS evaluates new tests.
Key Provisions
- Amends Medicare payment law to allow coverage of additional lung cancer screening tests.
- Requires covered tests to be FDA-cleared or FDA-approved preventive services.
- Authorizes HHS to define appropriate individuals, frequency, and payment limits.
- Builds on national coverage determination 210.14 instead of replacing existing lung cancer screening coverage.
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
Authorizes Medicare coverage for additional FDA-cleared or FDA-approved preventive lung cancer screening tests beyond the current national coverage determination when HHS sets appropriate frequency and payment limits.
Key Policy Areas
Medicare, Cancer Screening, Medical Devices
Primary Purpose
Authorizes Medicare coverage for additional FDA-cleared or FDA-approved preventive lung cancer screening tests beyond the current national coverage determination when HHS sets appropriate frequency and payment limits.
Policy Domains
Resolution provisions
Identified Gains
- Medicare beneficiaries
- Lung cancer patients
- Medical device manufacturers
- Radiology providers
Identified Costs
- Centers for Medicare and Medicaid Services
- Medicare contractors
- Medicare trust funds
- Clinical guideline organizations
Sponsors
Legislative Progress
In CommitteeMr. Buchanan (for himself, Mr. Kennedy of New York, Mr. …
Referred to the Committee on Energy and Commerce, and in …
Introduced in House
Stakeholder Effects
cui bono?How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.
Medicare beneficiaries, Medicare trust funds
Positive-direction: Medicare beneficiaries
Negative-direction: Medicare trust funds
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology